Company Media

asdasd

6 December 2021

Immuron (ASX:IMC) enters research agreement with Monash University

15 December 2020

Immuron (IMC) has entered a research agreement with Monash University to evaluate the efficacy of IMM-124E and advance SARS-CoV-2 findings.

Immuron (ASX:IMC) reveals positive anti-diarrhoea vaccine results

9 November 2020

Immuron (IMC) is surging on the ASX today after revealing some encouraging progress in the development of a treatment for diarrhoea.

Immuron (ASX:IMC) takes steps towards FDA approval for stomach bug treatment

12 October 2020

Biopharma company Immuron (IMC) is set to start clinical trials of its candidate drug, IMM124E, in collaboration with the U.S.-based Uniformed Services University.

Immuron's stock pulls back but still nearly doubles after stock offering

21 July 2020

Shares of Immuron Ltd. IMRN, -2.72% nearly doubled in premarket trading Tuesday, but pulled back sharply from earlier highs, after the Australia-based biopharmaceutical company announced a registered direct offering of 1.07 million American depositary....

Immuron’s commercially available products found to neutralise COVID-19 during in vitro research

21 July 2020

Biopharmaceutical company Immuron (ASX: IMC) has revealed the IMM-124E, which is used in its commercially available Travelan product, has demonstrated neutralising activity against COVID-19.

Could Immuron’s (ASX:IMC) traveller’s diarrhoea treatment be used to fight COVID-19?

21 July 2020

Immuron’s (IMC) share price has more than doubled on the news a drug used in its traveller’s diarrhoea formulation neutralises activity aginst the COVID-19 virus.

Immuron reveals anti-COVID potential, raises $28 million

20 July 2020

Hot on the heels of reporting anti-Covid-19 action by one of the drugs it is developing, biotechnology company Immuron has raised $28 million (US$20 million) from institutional investors.

Immuron (ASX:IMC) develops research agreement

22 June 2020

Biopharmaceutical company Immuron (IMC) has executed its previously announced research agreement involving the US Naval Medical Research Centre and the CSIRO.

Immuron and US Naval Medical Research Center prepare to develop novel oral therapeutic for E-Coli

10 June 2020

Dual-listed biopharmaceutical company Immuron (ASX: IMC) is on course to make progress with a new oral therapeutic to treat campylobacteriosis and E. coli infections after development partner Naval Medical Research Center (NMRC) requested a pre-IND....

Immuron's stock blasts off nearly 10-fold after partner NMRC seeks pre-IND meeting with FDA

9 June 2020

The U.S.-listed shares of Immuron Ltd.  skyrocketed nearly 10-fold on massive volume in afternoon trading Tuesday, after the Australia-based biopharmaceutical company said its research partner, the Naval Medical Research Center (NMRC) has requested.....

Diarrhea: A major health issue for Americans travelling abroad

12 February 2020

Research surveys have shown that around one in four travellers changes their travel itinerary due to diarrhoea and around 5% have to seek medical attention.

Walter Reid Army Institute of Research 2019 Year in Review

15 January 2020

The WRAIR provides unique research capabilities and innovative medical solutions to a range of Force Health Protection and Readiness challenges currently facing U.S. Service Members, along with threats anticipated during future operations.

Immuron partnering with Walter Reid Army Institute of Research to test Travelan against Shigella, ETEC, Vibrio cholerae and Campylobacter jejuni isolates (2020, WRAIR's Investigator's Dispatch)

1 January 2020

The WRAIR provides unique research capabilities and innovative medical solutions to a range of Force Health Protection and Readiness challenges currently facing U.S. Service Members, along with threats anticipated during future operations.

Immuron’s shares rise on the back of Travelan® results

12 June 2019

Australian biopharmaceutical group, Immuron Ltd (ASX:IMC; NASDQ:IMRN), has provided an extremely promising update on the company’s cooperative research and development agreements with the US Department of Defence, no doubt contributing to its strong share

Travelan on The Not Old Better Show with Dr. Hailey Weerts - Research Scientist of Walter Reed Army Institute of Research WRAIR

1 June 2019

Travelan featured on The Not Old Better Show with Dr.Hailey Weerts - Research Scientist of Walter Reed Army Institute of Research. Dr Hailey is currently engaged in the investigation of immune responses to Shigella vaccines in pre-clinical/ human clinical

Immuron CEO interviewed on the RedChip Money Report, USA

10 October 2018

Immuron CEO - Dr Jerry Kanellos interviewed on the Red Chip Money Report, USA. Immuron: Developing Innovative Immunotherapy Therapies for Gut-Mediated Diseases

Immuron and US Department of Defense look to develop silver bullet for gastro infections

16 July 2018

Biopharmaceutical company Immuron (ASX: IMC) is making significant territorial advances in its mission to develop and market a range of oral immunotherapeutics for the treatment of gut mediated pathogens.

US Defense finishes latest research on Immuron’s Travelan®

16 July 2018

The studies were designed to evaluate Travelan’s ability to neutralise pathogenic bacteria of interest, including Campylobacter, ETEC and Shigella bacterial infections. Travelan was shown to bind and was reactive to all strains of bacteria tested.

No crap: Immuron is one step closer to an anti-gastro pill

16 July 2018

In January, Immuron (ASX:IMC) released a study of its Travelan tablets by the DOD which showed its was effective in preventing travellers diarrhoea in 180 strains of campylobacter.